Broncodilatadores para la EPOC : cuadro resumen

https://mileon.wordpress.com/2015/05/28/broncodilatadores-para-la-epoc-cuadro-resumen/

El Dr. Borrego, adjunto del servicio de Medicina Interna del Hospital de León, ha realizado una actualización sobre el anterior cuadro de broncodilatadores, incluyendo los nuevos productos que se han comercializado en los últimos meses.

Actividad física en pacientes con EPOC : The PROactive instruments

http://erj.ersjournals.com/content/early/2015/05/28/09031936.00183014.long

Daily and clinical visit “PROactive physical activity in COPD” instruments are hybrid tools combining a short patient-reported outcome questionnaire and two activity monitor variables which provide simple, valid and reliable measures of physical activity in COPD patients.

Rinitis alérgica : guía de práctica clínica

http://oto.sagepub.com/content/152/1_suppl/S1.long

This clinical practice guideline was undertaken to optimize the care of patients with AR by addressing quality improvement opportunities through an evaluation of the available evidence and an assessment of the harm-benefit balance of various diagnostic and management options.

Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications

http://thorax.bmj.com/content/68/1/114.full?utm_content=HT_A6&utm_medium=Link6&utm_medium=email&utm_campaign=ATS&utm_campaign=Thorax_ATS&utm_source=landingpage&utm_source=marketing_email&keytype=ref&siteid=bmjjournals&utm_term=&ijkey=rx9mxHs129chk

Conclusions

The inhaled anticholinergic agents ipratropium and tiotropium have the potential to increase the risk of serious cardiovascular events, including mortality, when used in the treatment of COPD. 

The authors urge caution in prescribing inhaled anticholinergics for patients with pre-existing arrhythmias or cardiac disorders.

Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease

http://thorax.bmj.com/content/68/7/670.full?utm_source=landingpage&utm_medium=Link4&utm_campaign=ATS&utm_source=marketing_email&utm_medium=email&utm_campaign=Thorax_ATS&utm_content=HT_A4&utm_term=


Conclusions Fibrinogen is likely to be a useful biomarker to stratify individuals with COPD into those with a high or low risk of future exacerbations and may identify those with a higher risk of mortality.